Yu Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu Zhu has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Ming Hong
The First Affiliated Hospital of Nanjing Medical University
8 shared publicationsSixuan Qian
The First Affiliated Hospital of Nanjing Medical University
7 shared publicationsChun Qiao
The First Affiliated Hospital of Nanjing Medical University
6 shared publicationsYutian Lei
Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu, 210029
6 shared publicationsXiaoli Zhao
The First Affiliated Hospital of Nanjing Medical University
5 shared publicationsHuihui Zhao
Nanjing University of Chinese Medicine
4 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Venetoclax with azacitidine and dexamethasone: Non-cytotoxic induction therapy for T-cell leukemia and mixed-phenotype leukemia
Background: T-lineage acute leukemias are aggressive malignancies for which treatment options are limited. Objectives: This study evaluated the efficacy and safety of a non-cytotoxic regimen combining venetoclax, azacitidine, and dexamethasone (VAD) as first-line induction therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T/myeloid mixed-phenotype acute leukemia (T-Myeloid MPAL). Design: We retrospectively analyzed the clinical parameters and survival data of 11 patients with newly-diagnosed T-ALL or T-Myeloid MPAL who received the VAD regimen. Methods: The complete remission (CR) rate and adverse events were assessed. Kaplan–Meier curves were constructed to evaluate survival outcomes. Results: Among 11 patients (7 with early T-cell precursor [ETP] ALL, 2 with T-Myeloid MPAL, and 2 with non-ETP T-ALL), the overall CR rate after one cycle of VAD therapy was 90.9%, with 45.5% achieving measurable residual disease (MRD) negativity by flow cytometry. The historically poor-prognosis ETP-ALL subgroup showed an 85.7% CR rate (6/7), while both T-Myeloid MPAL cases attained MRD negativity. No tumor lysis syndrome or treatment-related mortality occurred. Over a median follow-up of 358 days, all 5 patients who received transplantations remained relapse-free. Conclusion: The VAD regimen demonstrated a high response rate and favorable safety, enabling effective transplantation bridging with avoidance of conventional cytotoxic therapy.
- 25 August 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessVenetoclax with azacitidine and dexamethasone: Non-cytotoxic induction therapy for T-cell leukemia and mixed-phenotype leukemia
Background: T-lineage acute leukemias are aggressive malignancies for which treatment options are limited. Objectives: This study evaluated the efficacy and safety of a non-cytotoxic regimen combining venetoclax, azacitidine, and dexamethasone (VAD) as first-line induction therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T/myeloid mixed-phenotype acute leukemia (T-Myeloid MPAL). Design: We retrospectively analyzed the clinical parameters and survival data of 11 patients with newly-diagnosed T-ALL or T-Myeloid MPAL who received the VAD regimen. Methods: The complete remission (CR) rate and adverse events were assessed. Kaplan–Meier curves were constructed to evaluate survival outcomes. Results: Among 11 patients (7 with early T-cell precursor [ETP] ALL, 2 with T-Myeloid MPAL, and 2 with non-ETP T-ALL), the overall CR rate after one cycle of VAD therapy was 90.9%, with 45.5% achieving measurable residual disease (MRD) negativity by flow cytometry. The historically poor-prognosis ETP-ALL subgroup showed an 85.7% CR rate (6/7), while both T-Myeloid MPAL cases attained MRD negativity. No tumor lysis syndrome or treatment-related mortality occurred. Over a median follow-up of 358 days, all 5 patients who received transplantations remained relapse-free. Conclusion: The VAD regimen demonstrated a high response rate and favorable safety, enabling effective transplantation bridging with avoidance of conventional cytotoxic therapy.
- 1 August 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (8) , 224
Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis
- 1 August 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (8) , 224
Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis
- Open Access
- 21 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis
Background: With life expectancies of patients with chronic myeloid leukemia (CML) now approaching those of the general population under tyrosine kinase inhibitor (TKI) therapy, understanding long-term treatment-related toxicities becomes paramount. Although imatinib’s nephrotoxic potential is established, the renal safety profiles of second-generation TKIs—dasatinib, nilotinib, and flumatinib—remain incompletely characterized. Methods: This single-center retrospective study analyzed renal function trajectories in 348 patients with CML receiving first-line imatinib, dasatinib, nilotinib, or flumatinib. Renal function was assessed using serum creatinine and estimated glomerular filtration rate (eGFR). Mixed-effects models incorporating treatment group, time, and their interaction as fixed effects were used to formally compare eGFR trajectories across treatment groups. Chronic renal adverse events and acute kidney injury were also evaluated. Results: Formal comparison of eGFR trajectories across treatment groups revealed a significant time × treatment interaction, indicating differential renal function changes among the 4 TKIs. Significant serum creatinine elevation and eGFR decline were observed in imatinib and flumatinib groups, contrasting with stable creatinine and divergent eGFR patterns in dasatinib (slight increase) and nilotinib (decline) groups. The incidence of chronic renal adverse events varied substantially across cohorts—12.3% (imatinib), 2.6% (nilotinib), 4.3% (dasatinib), and 9.6% (flumatinib). Notably, among 3 documented acute kidney injury cases, all occurred during flumatinib treatment. Furthermore, treatment-free remission achievement did not confer significant renal function recovery, suggesting potential irreversibility of established renal damage. Conclusion: TKIs exhibit differential renal safety profiles, underscoring the critical importance of individualized TKI selection based on baseline renal status and implementation of rigorous renal monitoring protocols throughout treatment duration.
- 21 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Open AccessRenal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis
Background: With life expectancies of patients with chronic myeloid leukemia (CML) now approaching those of the general population under tyrosine kinase inhibitor (TKI) therapy, understanding long-term treatment-related toxicities becomes paramount. Although imatinib’s nephrotoxic potential is established, the renal safety profiles of second-generation TKIs—dasatinib, nilotinib, and flumatinib—remain incompletely characterized. Methods: This single-center retrospective study analyzed renal function trajectories in 348 patients with CML receiving first-line imatinib, dasatinib, nilotinib, or flumatinib. Renal function was assessed using serum creatinine and estimated glomerular filtration rate (eGFR). Mixed-effects models incorporating treatment group, time, and their interaction as fixed effects were used to formally compare eGFR trajectories across treatment groups. Chronic renal adverse events and acute kidney injury were also evaluated. Results: Formal comparison of eGFR trajectories across treatment groups revealed a significant time × treatment interaction, indicating differential renal function changes among the 4 TKIs. Significant serum creatinine elevation and eGFR decline were observed in imatinib and flumatinib groups, contrasting with stable creatinine and divergent eGFR patterns in dasatinib (slight increase) and nilotinib (decline) groups. The incidence of chronic renal adverse events varied substantially across cohorts—12.3% (imatinib), 2.6% (nilotinib), 4.3% (dasatinib), and 9.6% (flumatinib). Notably, among 3 documented acute kidney injury cases, all occurred during flumatinib treatment. Furthermore, treatment-free remission achievement did not confer significant renal function recovery, suggesting potential irreversibility of established renal damage. Conclusion: TKIs exhibit differential renal safety profiles, underscoring the critical importance of individualized TKI selection based on baseline renal status and implementation of rigorous renal monitoring protocols throughout treatment duration.
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Blood and Lymphatic Cancer: Targets and Therapy
- Vol. ume 16, 1-15
Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia
- 1 July 2026
- Published by Taylor & Francis in Blood and Lymphatic Cancer: Targets and Therapy
- Vol. ume 16, 1-15
Open AccessLong-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia
- 10 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500967
Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis
PURPOSE: As survival rates among patients with chronic myeloid leukemia (CML) have improved significantly, treatment goals have expanded from disease control to optimizing long-term quality of life (QoL). METHODS: The multicenter cross-sectional study used relevant survey questionnaires to gather comprehensive data on baseline characteristics, clinical treatment, economic burdens, psychological status, adverse events (AEs), and QoL among patients with CML. RESULTS: In all, 2,035 valid questionnaires were included for analysis. Psychological burden assessments indicate a high prevalence of mental health symptoms: 38.5% of patients report experiencing anxiety symptoms, whereas 46% exhibit symptoms of depression. This study identified a high-burden group experiencing significant economic and psychological stressors, which are associated with poor clinical responses. Psychological burden is central to the psychosocial clinical network and exhibits the strongest correlation with QoL ( r = 0.64). Notably, the mediation model indicates that psychological burden fully mediates the effect of economic burden on QoL (85.3%) and partially mediates its influence on medication adherence (35.5%). Furthermore, we identified a clinically significant subgroup characterized as QoL lag—patients who achieve deep molecular response but report low QoL. This discrepancy is independently predicted by multiple AEs (≥6 types: OR = 2.09), serious AEs (OR = 1.90), comorbidities (OR = 2.44), and escalating psychological burden (OR = 1.59). CONCLUSION: The findings underscore the need to shift the treatment of CML toward a holistic management paradigm. Clinical practice must actively engage with patients' concerns to optimize treatment efficacy, adjust drug dosages appropriately, and integrate social resources to provide psychological, economic, and familial support.
- 10 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500967
Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis
PURPOSE: As survival rates among patients with chronic myeloid leukemia (CML) have improved significantly, treatment goals have expanded from disease control to optimizing long-term quality of life (QoL). METHODS: The multicenter cross-sectional study used relevant survey questionnaires to gather comprehensive data on baseline characteristics, clinical treatment, economic burdens, psychological status, adverse events (AEs), and QoL among patients with CML. RESULTS: In all, 2,035 valid questionnaires were included for analysis. Psychological burden assessments indicate a high prevalence of mental health symptoms: 38.5% of patients report experiencing anxiety symptoms, whereas 46% exhibit symptoms of depression. This study identified a high-burden group experiencing significant economic and psychological stressors, which are associated with poor clinical responses. Psychological burden is central to the psychosocial clinical network and exhibits the strongest correlation with QoL ( r = 0.64). Notably, the mediation model indicates that psychological burden fully mediates the effect of economic burden on QoL (85.3%) and partially mediates its influence on medication adherence (35.5%). Furthermore, we identified a clinically significant subgroup characterized as QoL lag—patients who achieve deep molecular response but report low QoL. This discrepancy is independently predicted by multiple AEs (≥6 types: OR = 2.09), serious AEs (OR = 1.90), comorbidities (OR = 2.44), and escalating psychological burden (OR = 1.59). CONCLUSION: The findings underscore the need to shift the treatment of CML toward a holistic management paradigm. Clinical practice must actively engage with patients' concerns to optimize treatment efficacy, adjust drug dosages appropriately, and integrate social resources to provide psychological, economic, and familial support.
- Open Access
- 11 February 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study
There is an increasing movement among chronic myeloid leukemia (CML) patients towards optimizing dosages and implementing personalized treatment plans. We
- 11 February 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessEfficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study
There is an increasing movement among chronic myeloid leukemia (CML) patients towards optimizing dosages and implementing personalized treatment plans. We
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Blood and Lymphatic Cancer: Targets and Therapy
- Vol. ume 15, 193-202
Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia
Purpose: This study evaluated the efficacy and safety of a 14-day blinatumomab-venetoclax (BV) regimen as induction therapy for newly diagnosed Ph-negative B-cell acute lymphoblastic leukemia (B-ALL), focusing on rapid remission and tolerability in unfit patients. Patients and Methods: Thirteen patients received venetoclax (100 mg on day 1, 200 mg on day 2, 300 mg on day 3, and 400 mg from days 4 to 14) with blinatumomab (9 to 28 ug/day) for 14 days. Bone marrow assessments were performed at days 14– 21. Primary endpoints were complete remission (CR) rate, minimal residual disease (MRD) negativity by flow cytometry, and adverse events. Results: The CR rate after one cycle of BV regimen was 92.3% (12/13), and all patients achieved MRD-negativity; 91.7% (11/12) achieved MRD clearance by day 21. Grade 1– 2 cytokine release syndrome occurred in 46.2% (6/13; 1 grade 3). Hematologic toxicity included grade 3– 4 neutropenia (92.3%) and thrombocytopenia (46.2%), with only 30.8% febrile neutropenia. All AEs resolved rapidly with supportive care, allowing therapy to continue without interruption. At median follow-up of 283 days, 1-year relapse-free survival rate and overall survival rate were 60.6% and 83.3%. Conclusion: The 14-day BV regimen induced rapid deep remission (91.7% MRD-negative by day 21) with manageable toxicity in Ph-negative B-ALL. Synergistic T-cell activation by venetoclax may explain enhanced efficacy.
- 1 November 2025
- Published by Taylor & Francis in Blood and Lymphatic Cancer: Targets and Therapy
- Vol. ume 15, 193-202
Open AccessVenetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia
Purpose: This study evaluated the efficacy and safety of a 14-day blinatumomab-venetoclax (BV) regimen as induction therapy for newly diagnosed Ph-negative B-cell acute lymphoblastic leukemia (B-ALL), focusing on rapid remission and tolerability in unfit patients. Patients and Methods: Thirteen patients received venetoclax (100 mg on day 1, 200 mg on day 2, 300 mg on day 3, and 400 mg from days 4 to 14) with blinatumomab (9 to 28 ug/day) for 14 days. Bone marrow assessments were performed at days 14– 21. Primary endpoints were complete remission (CR) rate, minimal residual disease (MRD) negativity by flow cytometry, and adverse events. Results: The CR rate after one cycle of BV regimen was 92.3% (12/13), and all patients achieved MRD-negativity; 91.7% (11/12) achieved MRD clearance by day 21. Grade 1– 2 cytokine release syndrome occurred in 46.2% (6/13; 1 grade 3). Hematologic toxicity included grade 3– 4 neutropenia (92.3%) and thrombocytopenia (46.2%), with only 30.8% febrile neutropenia. All AEs resolved rapidly with supportive care, allowing therapy to continue without interruption. At median follow-up of 283 days, 1-year relapse-free survival rate and overall survival rate were 60.6% and 83.3%. Conclusion: The 14-day BV regimen induced rapid deep remission (91.7% MRD-negative by day 21) with manageable toxicity in Ph-negative B-ALL. Synergistic T-cell activation by venetoclax may explain enhanced efficacy.
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Advances in Medical Education and Practice
- Vol. ume 16, 1651-1663
Developing a Framework of Entrustable Professional Activities for Residency Training in Hematology
Purpose: Entrustable professional activities (EPAs), essential for competent and safe clinical practice, serve as milestones to assess trainees’ readiness for independent patient care. This study aimed to develop a context-specific EPA framework for hematology residency training in China. Methods: We employed a modified Delphi method involving 35 experts from 8 academic hospitals to establish China’s inaugural hematology-specific EPA framework. The development process comprised three key components: (1) a systematic literature review integrating international EPA models with China’s the Standardized Training System for Residents (STSR) requirements; (2) structural validation through the EQual rubric (cut-off: 4.07); and (3) a two-round Delphi consultations evaluating importance, observability, evaluability, repeatability, feasibility and entrustment-supervision levels. Expert engagement metrics and inter-rater agreement evaluated consensus quality. Results: The preliminary 14-item framework was ultimately refined to 12 EPAs following the exclusion of “Public Health Emergency Response” (EPA 14; mean score=3.23) and “Imparting Bad News” (EPA 13; 57.1% experts advocated removing). Key revisions involved expanding the hematopoietic stem cell transplantation (HSCT) competency domain to include donor selection (EPA 7) and the provisional addition then subsequent removal of “Cellular Immunotherapy Complications Management” due to insufficient standardization of assessment criteria. The final EPAs achieved unanimous EQual compliance (≥ 4.07) and strong Delphi consensus (Kendall’s W: Round 1 = 0.271, Round 2 = 0.529, p< 0.001). Clinical entrustment-supervision levels were systematically stratified by training phase and expected competency at graduation. Conclusion: This study has established China’s first hematology-specific EPA framework by addressing gaps in global EPA models through integration of integrating local clinical demands (high patient volume, resource constraints) and multidisciplinary coordination. The framework provides a validated tool for competency-based assessment, with future steps focusing on digital implementation and nationwide validation.
- 1 September 2025
- Published by Taylor & Francis in Advances in Medical Education and Practice
- Vol. ume 16, 1651-1663
Open AccessDeveloping a Framework of Entrustable Professional Activities for Residency Training in Hematology
Purpose: Entrustable professional activities (EPAs), essential for competent and safe clinical practice, serve as milestones to assess trainees’ readiness for independent patient care. This study aimed to develop a context-specific EPA framework for hematology residency training in China. Methods: We employed a modified Delphi method involving 35 experts from 8 academic hospitals to establish China’s inaugural hematology-specific EPA framework. The development process comprised three key components: (1) a systematic literature review integrating international EPA models with China’s the Standardized Training System for Residents (STSR) requirements; (2) structural validation through the EQual rubric (cut-off: 4.07); and (3) a two-round Delphi consultations evaluating importance, observability, evaluability, repeatability, feasibility and entrustment-supervision levels. Expert engagement metrics and inter-rater agreement evaluated consensus quality. Results: The preliminary 14-item framework was ultimately refined to 12 EPAs following the exclusion of “Public Health Emergency Response” (EPA 14; mean score=3.23) and “Imparting Bad News” (EPA 13; 57.1% experts advocated removing). Key revisions involved expanding the hematopoietic stem cell transplantation (HSCT) competency domain to include donor selection (EPA 7) and the provisional addition then subsequent removal of “Cellular Immunotherapy Complications Management” due to insufficient standardization of assessment criteria. The final EPAs achieved unanimous EQual compliance (≥ 4.07) and strong Delphi consensus (Kendall’s W: Round 1 = 0.271, Round 2 = 0.529, p< 0.001). Clinical entrustment-supervision levels were systematically stratified by training phase and expected competency at graduation. Conclusion: This study has established China’s first hematology-specific EPA framework by addressing gaps in global EPA models through integration of integrating local clinical demands (high patient volume, resource constraints) and multidisciplinary coordination. The framework provides a validated tool for competency-based assessment, with future steps focusing on digital implementation and nationwide validation.
- Open Access
- 13 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1408-1415
Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
Summary: We studied 60 chronic myeloid leukaemia (CML) patients with a prior history of accelerated phase (AP) including de novo AP (n = 19) and transformation to AP (n = 4), or tyrosine kinase inhibitor (TKI) therapy failure in the chronic phase (CP, n = 37), who discontinued TKI therapy. Median interval from diagnosis with AP or TKI therapy failure to achieving a deep molecular response (DMR) was 19 months (interquartile range [IQR], 9–30 months). Median TKI treatment and DMR duration were 108 months (IQR, 72–137 months) and 59 months (IQR, 39–87 months) respectively. At a median follow‐up of 21 months (IQR, 11–36 months) after TKI discontinuation, 19 (31%) patients lost the major molecular response (MMR). The 3‐year probability of a sustained MMR was 59% (95% confidence interval [CI], [45%, 78%]). In the multivariable analyses, age at discontinuation 0.1% at 12 months on TKI therapy (reference, ≤0.1%; HR = 3.9 [1.4, 11.5], p = 0.011) were significantly associated with a higher probability of MMR loss after TKI discontinuation. CML patients with a history of AP or TKI therapy failure may achieve successful treatment‐free remission after an adequate TKI therapy duration and a sustained DMR.
- 13 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1408-1415
Open AccessTreatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
Summary: We studied 60 chronic myeloid leukaemia (CML) patients with a prior history of accelerated phase (AP) including de novo AP (n = 19) and transformation to AP (n = 4), or tyrosine kinase inhibitor (TKI) therapy failure in the chronic phase (CP, n = 37), who discontinued TKI therapy. Median interval from diagnosis with AP or TKI therapy failure to achieving a deep molecular response (DMR) was 19 months (interquartile range [IQR], 9–30 months). Median TKI treatment and DMR duration were 108 months (IQR, 72–137 months) and 59 months (IQR, 39–87 months) respectively. At a median follow‐up of 21 months (IQR, 11–36 months) after TKI discontinuation, 19 (31%) patients lost the major molecular response (MMR). The 3‐year probability of a sustained MMR was 59% (95% confidence interval [CI], [45%, 78%]). In the multivariable analyses, age at discontinuation 0.1% at 12 months on TKI therapy (reference, ≤0.1%; HR = 3.9 [1.4, 11.5], p = 0.011) were significantly associated with a higher probability of MMR loss after TKI discontinuation. CML patients with a history of AP or TKI therapy failure may achieve successful treatment‐free remission after an adequate TKI therapy duration and a sustained DMR.
- Open Access
- 26 May 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-14
LRRFIP1 enhances the Wnt/β-catenin pathway by binding to DVLs in myelodysplastic syndrome
Due to high heterogeneity, diagnosing MDS can be challenging. Consequently, investigating its pathogenesis and progression mechanisms, and seeking novel targets for diagnosis and treatment, are critical issues that require urgent attention. This study aimed to investigate whether LRRFIP1 might contribute to MDS pathogenesis by modulating the Wnt/β-catenin signaling pathway. In MDS cell lines, mRNA transcriptome sequencing and Dual luciferase reporter gene assays were employed to assess Wnt/β-catenin signaling pathway activity. To explore the biological characteristics of MDS cell lines, CCK8, Annexin-V APC/7-AAD and Annexin V-FITC/PI double staining and fluorescence TUNEL assay, and PI single staining were used. In MDS cell lines, proliferation was notably higher in LRRFIP1-overexpressing cells compared to silenced ones, while cell apoptosis was lower in the former. mRNA transcriptome sequencing revealed LRRFIP1's involvement in modulating the Wnt/β-catenin signaling pathway. LRRFIP1 was found to positively regulate Wnt/β-catenin pathway activity, and synergy between LRRFIP1 and Dvl was observed in enhancing canonical Wnt signaling. LRRFIP1 overexpression significantly upregulated key genes in Wnt signaling pathway (such as β-catenin, Dvl2, Dvl3 and Wnt) at the mRNA level, and notably upregulated non-phosphorylated β-catenin at the protein level. Moreover, BCL-2 and CyclinD1 protein expression was significantly higher in LRRFIP1-overexpressing cells compared to silenced ones, with even greater expression observed in LRRFIP1/Dvl3 co-overexpressing cells. LRRFIP1 can promote the proliferation of MDS cells and inhibit apoptosis, and LRRFIP1 and Dvl can synergistically enhance the activity of the Wnt/β-catenin signaling pathway in MDS, thus providing evidence for LRRFIP1's involvement in the pathogenesis of MDS.
- 26 May 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-14
Open AccessLRRFIP1 enhances the Wnt/β-catenin pathway by binding to DVLs in myelodysplastic syndrome
Due to high heterogeneity, diagnosing MDS can be challenging. Consequently, investigating its pathogenesis and progression mechanisms, and seeking novel targets for diagnosis and treatment, are critical issues that require urgent attention. This study aimed to investigate whether LRRFIP1 might contribute to MDS pathogenesis by modulating the Wnt/β-catenin signaling pathway. In MDS cell lines, mRNA transcriptome sequencing and Dual luciferase reporter gene assays were employed to assess Wnt/β-catenin signaling pathway activity. To explore the biological characteristics of MDS cell lines, CCK8, Annexin-V APC/7-AAD and Annexin V-FITC/PI double staining and fluorescence TUNEL assay, and PI single staining were used. In MDS cell lines, proliferation was notably higher in LRRFIP1-overexpressing cells compared to silenced ones, while cell apoptosis was lower in the former. mRNA transcriptome sequencing revealed LRRFIP1's involvement in modulating the Wnt/β-catenin signaling pathway. LRRFIP1 was found to positively regulate Wnt/β-catenin pathway activity, and synergy between LRRFIP1 and Dvl was observed in enhancing canonical Wnt signaling. LRRFIP1 overexpression significantly upregulated key genes in Wnt signaling pathway (such as β-catenin, Dvl2, Dvl3 and Wnt) at the mRNA level, and notably upregulated non-phosphorylated β-catenin at the protein level. Moreover, BCL-2 and CyclinD1 protein expression was significantly higher in LRRFIP1-overexpressing cells compared to silenced ones, with even greater expression observed in LRRFIP1/Dvl3 co-overexpressing cells. LRRFIP1 can promote the proliferation of MDS cells and inhibit apoptosis, and LRRFIP1 and Dvl can synergistically enhance the activity of the Wnt/β-catenin signaling pathway in MDS, thus providing evidence for LRRFIP1's involvement in the pathogenesis of MDS.